Victoria Johnson

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

This preview of RWCS 2026 highlights some of the sessions and interviews to look forward to.

This rheumatology month in review emphasizes new data and FDA actions.

Arthur Mandelin, MD, PhD, and Daniel White, MS, ScD, share what they consider the largest current unmet need in the RA field.

A recent study reveals that treating gout effectively lowers cardiovascular risks, highlighting the importance of personalized urate-lowering therapy.

A recent trial reveals that transcutaneous auricular vagus nerve stimulation does not significantly reduce pain in erosive hand osteoarthritis compared to placebo.

Abatacept shows potential to delay rheumatoid arthritis progression for up to four years, but benefits diminish after treatment cessation.

Positive data from a phase 2 study were previously presented at the 2025 ACR Convergence.

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

This FDA News Month in Review provides a round-up of regulatory decisions from December 2025.

The rheumatoid arthritis year in review highlights FDA approvals, data, and advances in 2025.

The fibromyalgia year in review highlights FDA approvals, data, and advances in 2025.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

This rheumatology month in review emphasizes new data from the ACR Convergence.

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

Ianalumab significantly reduces Sjögren disease activity, meeting the primary outcome in recent phase 3 trials.

Mepolizumab shows significant real-world benefits in reducing end-organ dysfunction.